City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Joanne Mortimer, MD  
Search results:  9  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-9 Trials Jump to page:

COH Protocol Number: 17152 ClinicalTrials.gov Number: NCT03078751

Principal Investigator: Joanne Mortimer, MD
Sponsor: Industrial

Title:  A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as an Adjuvant Treatment in Patients with Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer

COH Protocol Number: 17066 ClinicalTrials.gov Number: NCT03145909

Principal Investigator: Joanne Mortimer, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

COH Protocol Number: 16451 ClinicalTrials.gov Number: NCT02954874

Principal Investigator: Joanne Mortimer, MD
Sponsor: Cooperative Group

Title:  SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >= 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

COH Protocol Number: 16080 ClinicalTrials.gov Number: NCT02032823

Principal Investigator: Joanne Mortimer, MD
Sponsor: Cooperative Group

Title:  NRG Oncology NRG/NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

COH Protocol Number: 16079 ClinicalTrials.gov Number: NCT02827877

Principal Investigator: Joanne Mortimer, MD
Sponsor: Institutional

Title:  Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-based Neoadjuvant Therapy

COH Protocol Number: 15317

Principal Investigator: Joanne Mortimer, MD
Sponsor: Institutional

Title:  A Novel Single Wave Assessment to Measure Cardiac Dysfunction and Metabolic Syndrome in Cancer Patients

COH Protocol Number: 12147 ClinicalTrials.gov Number: NCT01730833

Principal Investigator: Joanne Mortimer, MD
Sponsor: NCI Approved External Peer Review

Title:  Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients with HER-2 Positive Advanced Breast Cancer

COH Protocol Number: 07100

Principal Investigator: Joanne Mortimer, MD
Sponsor: Institutional

Title:  Long Term Follow-Up After Breast Cancer

COH Protocol Number: 97105

Principal Investigator: Joanne Mortimer, MD
Sponsor: Institutional

Title:  Evaluation of Breast Cancer Patterns and Outcomes of Care

 
Results per page: 25 50 100 All 1-9 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.